How is SS-31 dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds SS-31 (Elamipretide) and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
The US label for Forzinity (elamipretide), for Barth syndrome in patients weighing at least 30 kg, gives 40 mg under the skin once daily, or 20 mg under the skin once daily in adults with an eGFR under 30 mL/minute who are not on dialysis.1
The guide's example
1 mg of SS-31 (Elamipretide) from a 10 mg vial mixed with 1 mL is 10 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 10 mg58% set up9 | 10 mg/mL: 1 mg is 10 units, 2 mg is 20 units, 5 mg is 50 units | 5 mg/mL: 1 mg is 20 units, 2 mg is 40 units, 5 mg is 100 units |
| 50 mg32% set up9 | 50 mg/mL: 1 mg is 2 units, 2 mg is 4 units, 5 mg is 10 units | 25 mg/mL: 1 mg is 4 units, 2 mg is 8 units, 5 mg is 20 units |
Most often logged by Milligram users: 1 mg, 34% logged.9
Mixing the 10 or 50 mg vials people log, in syringe units
The label's product is an aqueous solution of 280 mg in 3.5 mL (80 mg/mL) in single-patient-use vials, not a powder.1 Searches of PubMed for elamipretide with stability, reconstitution or lyophilisation turned up no stability or reconstitution study of a powder, so none of the sources here gives a water volume for a powder. Among people who logged SS-31, 58% set up a 10 mg vial and 32% a 50 mg vial.9 The mixes people set up were 10 mg with 1 mL (29%), 10 mg with 2 mL (23%), 50 mg with 2 mL (15%) and 50 mg with 3 mL (13%).9 The doses people set up were 1 mg (34%), 2 mg (23%) and 5 mg (14%).9
1 mg of SS-31 (Elamipretide) from a 10 mg vial mixed with 1 mL is 10 units on a U-100 syringe.
Doses and schedules: label and trials
The label for Forzinity, approved under accelerated approval for adult and pediatric patients with Barth syndrome weighing at least 30 kg, gives 40 mg under the skin once daily at the same time each day.1 For adults with an eGFR under 30 mL/minute who are not on dialysis it gives 20 mg under the skin once daily.1 FDA's review says the sponsor ran no dose-ranging study in people with Barth syndrome.2 A registry record for SPIMD-301 (NCT05162768) describes a 48-week trial of 60 mg a day under the skin or placebo, 1:1, in primary mitochondrial disease from nuclear DNA mutations.3
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| TAZPOWER (SPIBA-201), Thompson45 | 40 mg a day under the skin, or placebo, crossover | 12 with Barth syndrome | 12 weeks each, 4-week washout |
| TAZPOWER extension, Thompson5 | 40 mg a day under the skin, open label | Ten with Barth syndrome entered, 8 reached week 168 | 168-week extension; the label says three of the 8 received it for 192 weeks1 |
| MMPOWER-3, Karaa6 | 40 mg once daily under the skin, or placebo, 1:1 | 218 adults with primary mitochondrial myopathy (109 per arm) | 24 weeks |
| ReCLAIM-2, Ehlers7 | 40 mg a day under the skin, or placebo | 176 with age-related macular degeneration (117 elamipretide, 59 placebo) | 48 weeks |
| PROGRESS-HF, Butler8 | 4 mg or 40 mg once daily under the skin, or placebo, 1:1:1 | 71 with heart failure with reduced ejection fraction | 28 days |
Where it is injected
The label says to inject under the skin in the abdomen (at least 2 inches from the navel) or the outer thigh, and to rotate the site daily.1 It reports comparable exposure after injection into the thigh or the abdomen.1 Of the people who logged SS-31, 98% logged it under the skin.9
Storage
The label says to store vials refrigerated at 2 to 8 degrees C, not frozen.1 It says that after the first dose the vial in use can be kept refrigerated at 2 to 8 degrees C or at 20 to 25 degrees C, and to discard vials 8 days after first opening.1 Those conditions are the label's, for its solution of 280 mg in 3.5 mL, not for a vial mixed from powder.1
Frequently asked questions
How was the 40 mg dose chosen?
FDA's review says the sponsor based it mainly on SPIMM-201, a crossover study in 36 people aged 16 to 65 with mitochondrial myopathy that gave placebo or 0.02, 0.20 or 0.50 mg/kg into a vein once daily for 5 days.2 It adds that the later phase 3 trial, SPIMM-301, at 40 mg in people with primary mitochondrial myopathy, showed no improvement in 6-minute walk distance except in a post-hoc subgroup with nuclear DNA mutations, which raised uncertainty about the 40 mg daily dose for Barth syndrome.2
- SS-31Half-life, trials and FDA status.
- SS-31 calculatorMixing calculator set up for SS-31.
- Metabolic peptidesThe compound group.
- Mixing guideGeneral steps for mixing a vial.
- MOTS-c dosageA guide for another compound.
- NAD injection dosageA guide for another compound.
- 5-amino-1MQ dosageA guide for another compound.
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- US Food and Drug Administration (label on DailyMed, Stealth BioTherapeutics). FORZINITY (elamipretide hydrochloride) injection, prescribing information and Instructions for Use (DailyMed, version 11). 2026. dailymed.nlm.nih.gov
- US Food and Drug Administration, Center for Drug Evaluation and Research. Integrated review, NDA 215244, Forzinity (elamipretide). 2025. accessdata.fda.gov
- ClinicalTrials.gov. Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (NCT05162768). 2025. clinicaltrials.gov
- Journal article (PMC, open access). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome (Thompson et al.). 2021. pmc.ncbi.nlm.nih.gov
- Genetics in Medicine (PubMed abstract). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER (abstract). 2024. pubmed.ncbi.nlm.nih.gov
- Neurology (PMC, open access). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. 2023. pmc.ncbi.nlm.nih.gov
- Ophthalmology Science (PMC, open access). ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration. 2025. pmc.ncbi.nlm.nih.gov
- Journal of Cardiac Failure (PubMed abstract). Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial (abstract). 2020. pubmed.ncbi.nlm.nih.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted